In the late 1930s, Hofmann became famous for synthesizing lysergic acid diethylamide, or LSD, while studying ergot alkaloids. His work was based on the modification of natural compounds found in the ergot fungus, which typically grows on grains like rye. Hofmann was well aware of the anecdotal and indigenous use of morning glory seeds for their psychoactive effects and hypothesized that a similar fungal relationship must exist within those plants. He suspected that a "hidden" fungus, closely related to the ergot found on rye, was the true manufacturer of the alkaloids found in morning glories.
Despite his brilliance and the efforts of many researchers who followed him, the specific fungus remained a ghost in the machinery of the plant. Panaccione explained that while researchers could easily detect high concentrations of lysergic acid derivatives in the plants, the source of those chemicals was never found. The plants and the fungi live in a symbiotic relationship, where the fungus produces the alkaloids to protect the plant from herbivores and pests, and the plant provides a stable environment for the fungus to thrive. Because the fungus is so integrated into the plant’s tissues and is often present in very small amounts in specific locations, it remained "clandestine" until Hazel’s discovery.
The name Periglandula clandestina was chosen specifically to honor this history of evasion. The term "clandestina" refers to the organism’s ability to remain hidden from investigators for nearly a century. This naming reflects both the biological reality of the fungus and the persistence required to finally bring it to light.
The implications for medicine are vast. Ergot alkaloids are a class of compounds with a complex reputation. In nature, they can be highly toxic; when consumed inadvertently through contaminated grain, they can cause ergotism, a dangerous condition characterized by hallucinations and vasoconstriction. However, when isolated and administered in precise, controlled dosages, these same chemicals are incredibly effective therapeutic agents. Currently, ergot-derived drugs are used to treat a variety of serious conditions, including debilitating migraines, Parkinson’s disease, dementia, and uterine hemorrhaging following childbirth.
The discovery of Periglandula clandestina is particularly exciting because the fungus is highly efficient at producing these alkaloids in large quantities. This efficiency suggests that the fungus could serve as a biological factory for pharmaceutical precursors. By studying the genetic makeup and the metabolic pathways of this specific fungus, scientists may be able to engineer ways to produce therapeutic compounds more reliably and with fewer side effects.
Panaccione noted that the "toxicity" of a substance is often a matter of dosage and delivery. By gaining a deeper understanding of how this fungus synthesizes ergot alkaloids, researchers can look for ways to modify the chemicals to retain their medicinal benefits while stripping away the unwanted physical or psychological side effects that currently limit their use. This is a primary concern for both the medical community and the agricultural industry, as these chemicals play a role in both human health and plant protection.
